NRXPNRX Pharmaceuticals, Inc.

Nasdaq nrxpharma.com


$ 2.73 $ 0.02 (0.75 %)    

Tuesday, 25-Jun-2024 11:51:24 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 2.69
$ 2.70
$ 0.00 x 0
$ 0.00 x 0
$ 2.70 - $ 2.73
$ 1.90 - $ 54.00
27,989
na
23.81M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-21-2021 03-31-2021 10-Q
13 04-01-2021 12-31-2020 10-K
14 11-16-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-15-2020 03-31-2020 10-Q
17 03-30-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 03-15-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-08-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 03-23-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nrx-pharmaceuticals-publishes-shareholder-update-letter-update-highlights-potential-implications-of-the-companys-recent-activities-at-the-annual-meeting-of-the-american-society-of-clinical-psychopharmacology

The June 2024 meeting of the American Society for Clinical Psychopharmacology (ASCP) focused heavily on increasing use of intra...

 ascendiant-capital-maintains-buy-on-nrx-pharmaceuticals-lowers-price-target-to-43

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target fro...

 nrx-pharmaceuticals-presents-landmark-trial-of-nrx-101-in-suicidal-bipolar-depression-at-the-ascp-annual-meeting-nrx-101-is-the-first-oral-antidepressant-demonstrated-to-reduce-suicidality-in-bipolar-depression

Poster presentation of "A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidon...

 nrx-pharmaceuticals-q1-eps-074-misses-037-estimate

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of...

 why-is-nrx-pharmaceuticals-stock-falling-after-data-from-suicidal-bipolar-depression-study

NRX Pharmaceuticals announces Phase 2b/3 trial findings of NRX-101 vs. Lurasidone for Suicidal Bipolar Depression.

 dow-surges-over-100-points-dr-horton-posts-upbeat-earnings

U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the market...